Medytox candidates bolster Allergan's neurotoxin pipeline
This article was originally published in Scrip
In an apparent move to build on its large and growing Botox franchise, Allergan has paid $65m up front to acquire worldwide rights outside South Korea to selected neurotoxin product candidates being developed by the small South Korean firm Medytox.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.